Molly Sullan, Ph.D. is a clinical research neuropsychologist and Director of Clinical Research at the Center for Psychedelic Research at the University of Colorado Denver. Her research focuses on the therapeutic potential of psychedelic compounds—including natural and synthetic iboga analogs—to promote neural repair, functional recovery, and symptom mitigation in complex neurological disorders, with a primary emphasis on traumatic brain injury (TBI) and other neurologic disorders. She specializes in the design, development, and execution of rigorous clinical trial methodologies, translating experimental therapeutics into scalable human protocols. In addition, she brings deep expertise in evaluating a broad spectrum of neurological and neurodevelopmental conditions, leveraging advanced neuropsychological frameworks and quantitative analytics to assess cognitive, emotional, and neurobiological outcomes across clinical trials.
Wednesday | 11.04.26 5:30-6:30pm MST
“Psychedelic-Assisted Treatment for Neurologic Disorders ”
Featuring Speaker:
Click HERE to Join Meeting ID: 993 7679 6255 Passcode: AIG
Presents:
UNM Academic Interest Group for Psychedelic Assisted Therapies and Research Presents:
Molly Sullan, PhD Assistant Professor University of Colorado
Join us via Zoom